The facts in this briefing are drawn from an SEC EDGAR Form 8-K filed and published on January 23, 2024. No other source documents are referenced in the available record.
On the financial advisory side, Lazard is acting as exclusive financial advisor to Sanofi, the acquirer, in a lead role. Centerview Partners LLC is acting as exclusive financial advisor to Inhibrx, the target, also in a lead capacity.
Legal counsel follows the same structural split. Weil, Gotshal & Manges LLP is serving as legal counsel to Sanofi, the acquirer. Paul, Weiss, Rifkind, Wharton and Garrison LLP is serving as legal counsel to Inhibrx, the target.
The facts block specifies that the transaction's structure includes a spin-off of non-core assets alongside the core merger, with consideration consisting of a combination of cash, a contingent value right, and stock. However, no further detail is given on the specific allocation among cash, CVR, and stock, the CVR's milestone triggers or payout terms, or the mechanics of the non-core asset spin-off.
Several material facts are not disclosed in the available record. No expected closing date is given. The specific breakdown of the cash, CVR, and stock components of consideration is not disclosed beyond their inclusion in the structure. No sector classification is given for either Inhibrx or Sanofi in this facts block, and no detail is provided on what regulatory approvals remain outstanding.